Alzheimer Disease

Alena Savonenko, Tatiana Melnikova, Tong Li, Donald L. Price, Philip Chun Wong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Significant progress has been made since the 1980s in understanding the neurobiology of Alzheimer disease (AD). The clinical syndrome of AD results from synaptic dysfunction and death of neurons in specific brain regions and circuits, particularly populations of nerve cells subserving memory and cognition. The pathological hallmarks are the extracellular deposition of -pleated assemblies of A-peptide (amyloid plaques) and intracellular aggregates of hyperphosphorylated tau protein (neurofibrillary tangles). Utilization of transgenic models of AD has advanced understanding of the pathogenesis of this disease and resulted in the discovery of therapeutic targets. The first attempts to implement novel antiamyloid treatments in mild to moderate AD had disappointing results, suggesting that therapy should be given much earlier in the course of the disease. Recognition that pathophysiological processes of AD begin decades before clinical symptoms appear calls for the development of tools for early diagnosis (imaging and biomarkers) and early treatment.

Original languageEnglish (US)
Title of host publicationNeurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders
PublisherElsevier Inc.
Pages321-338
Number of pages18
ISBN (Print)9780123982803, 9780123982704
DOIs
StatePublished - Dec 3 2014

Fingerprint

Alzheimer Disease
Neurons
tau Proteins
Neurofibrillary Tangles
Neurobiology
Amyloid Plaques
Therapeutics
Cognition
Early Diagnosis
Biomarkers
Peptides
Brain
Population

Keywords

  • Amyloid cascade hypothesis
  • Combination therapy
  • Mild cognitive impairment
  • Mouse model
  • Passive immunization
  • Secretase inhibition

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Savonenko, A., Melnikova, T., Li, T., Price, D. L., & Wong, P. C. (2014). Alzheimer Disease. In Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders (pp. 321-338). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-398270-4.00021-5

Alzheimer Disease. / Savonenko, Alena; Melnikova, Tatiana; Li, Tong; Price, Donald L.; Wong, Philip Chun.

Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc., 2014. p. 321-338.

Research output: Chapter in Book/Report/Conference proceedingChapter

Savonenko, A, Melnikova, T, Li, T, Price, DL & Wong, PC 2014, Alzheimer Disease. in Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc., pp. 321-338. https://doi.org/10.1016/B978-0-12-398270-4.00021-5
Savonenko A, Melnikova T, Li T, Price DL, Wong PC. Alzheimer Disease. In Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc. 2014. p. 321-338 https://doi.org/10.1016/B978-0-12-398270-4.00021-5
Savonenko, Alena ; Melnikova, Tatiana ; Li, Tong ; Price, Donald L. ; Wong, Philip Chun. / Alzheimer Disease. Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders. Elsevier Inc., 2014. pp. 321-338
@inbook{2233c46ffe514c6c8cb540052eb108aa,
title = "Alzheimer Disease",
abstract = "Significant progress has been made since the 1980s in understanding the neurobiology of Alzheimer disease (AD). The clinical syndrome of AD results from synaptic dysfunction and death of neurons in specific brain regions and circuits, particularly populations of nerve cells subserving memory and cognition. The pathological hallmarks are the extracellular deposition of -pleated assemblies of A-peptide (amyloid plaques) and intracellular aggregates of hyperphosphorylated tau protein (neurofibrillary tangles). Utilization of transgenic models of AD has advanced understanding of the pathogenesis of this disease and resulted in the discovery of therapeutic targets. The first attempts to implement novel antiamyloid treatments in mild to moderate AD had disappointing results, suggesting that therapy should be given much earlier in the course of the disease. Recognition that pathophysiological processes of AD begin decades before clinical symptoms appear calls for the development of tools for early diagnosis (imaging and biomarkers) and early treatment.",
keywords = "Amyloid cascade hypothesis, Combination therapy, Mild cognitive impairment, Mouse model, Passive immunization, Secretase inhibition",
author = "Alena Savonenko and Tatiana Melnikova and Tong Li and Price, {Donald L.} and Wong, {Philip Chun}",
year = "2014",
month = "12",
day = "3",
doi = "10.1016/B978-0-12-398270-4.00021-5",
language = "English (US)",
isbn = "9780123982803",
pages = "321--338",
booktitle = "Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Alzheimer Disease

AU - Savonenko, Alena

AU - Melnikova, Tatiana

AU - Li, Tong

AU - Price, Donald L.

AU - Wong, Philip Chun

PY - 2014/12/3

Y1 - 2014/12/3

N2 - Significant progress has been made since the 1980s in understanding the neurobiology of Alzheimer disease (AD). The clinical syndrome of AD results from synaptic dysfunction and death of neurons in specific brain regions and circuits, particularly populations of nerve cells subserving memory and cognition. The pathological hallmarks are the extracellular deposition of -pleated assemblies of A-peptide (amyloid plaques) and intracellular aggregates of hyperphosphorylated tau protein (neurofibrillary tangles). Utilization of transgenic models of AD has advanced understanding of the pathogenesis of this disease and resulted in the discovery of therapeutic targets. The first attempts to implement novel antiamyloid treatments in mild to moderate AD had disappointing results, suggesting that therapy should be given much earlier in the course of the disease. Recognition that pathophysiological processes of AD begin decades before clinical symptoms appear calls for the development of tools for early diagnosis (imaging and biomarkers) and early treatment.

AB - Significant progress has been made since the 1980s in understanding the neurobiology of Alzheimer disease (AD). The clinical syndrome of AD results from synaptic dysfunction and death of neurons in specific brain regions and circuits, particularly populations of nerve cells subserving memory and cognition. The pathological hallmarks are the extracellular deposition of -pleated assemblies of A-peptide (amyloid plaques) and intracellular aggregates of hyperphosphorylated tau protein (neurofibrillary tangles). Utilization of transgenic models of AD has advanced understanding of the pathogenesis of this disease and resulted in the discovery of therapeutic targets. The first attempts to implement novel antiamyloid treatments in mild to moderate AD had disappointing results, suggesting that therapy should be given much earlier in the course of the disease. Recognition that pathophysiological processes of AD begin decades before clinical symptoms appear calls for the development of tools for early diagnosis (imaging and biomarkers) and early treatment.

KW - Amyloid cascade hypothesis

KW - Combination therapy

KW - Mild cognitive impairment

KW - Mouse model

KW - Passive immunization

KW - Secretase inhibition

UR - http://www.scopus.com/inward/record.url?scp=84942114314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942114314&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-398270-4.00021-5

DO - 10.1016/B978-0-12-398270-4.00021-5

M3 - Chapter

SN - 9780123982803

SN - 9780123982704

SP - 321

EP - 338

BT - Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders

PB - Elsevier Inc.

ER -